AstraZeneca’s IMFINZI Combination Cuts Bladder Cancer Recurrence Risk 49%
Positive Phase III VOLGA trial results showed perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42%.
Positive Phase III VOLGA trial results showed perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42%.